• June 16, 2019

Nebula Genomics Signs Agreement for Pilot Project with EMD Serono - Odessa American: Business

e-Edition Subscribe

Nebula Genomics Signs Agreement for Pilot Project with EMD Serono

Print
Font Size:
Default font size
Larger font size

Posted: Tuesday, June 11, 2019 8:01 am

SAN FRANCISCO, & BOSTON--(BUSINESS WIRE)--Jun 11, 2019--

Nebula Genomics, which operates a technology platform containing genome-sequencing data, has signed an agreement with EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, for EMD Serono to access genomic data on Nebula’s blockchain-based network for genomic data sharing.

Nebula aims to help EMD Serono enhance its research efforts by supporting its scientists as they develop potential new medicines, using Nebula’s network of anonymized genomic data.

“This collaboration pioneers a new business model in personal genomics that benefits both individuals and researchers such as those at EMD Serono,” said Dennis Grishin, Chief Scientific Officer of Nebula Genomics. “We want to help patients benefit from their data and also empower them to actively contribute to research. Our goal is to spearhead a more patient-centric approach to medical research where pharmaceutical companies and patients are working together to accelerate drug development.”

Genomics has the potential to transform healthcare and biomedical research. As researchers are hindered by the overall lack of data as well as difficult data access due to data fragmentation and inefficient consent management, Nebula’s platform offers a solution to tackle these challenges. It connects patients and consumers with researchers and incentivizes data sharing by ensuring equitable compensation, transparency and security.

About EMD Serono, Inc.

EMD Serono - the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada – is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases. The business is committed to transforming lives by developing and delivering meaningful solutions that help address the therapeutic and support needs of individual patients. Building on a proven legacy and deep expertise in neurology, fertility and endocrinology, EMD Serono is developing potential new oncology and immuno-oncology medicines while continuing to explore potential therapeutic options for diseases such as psoriasis, lupus and multiple sclerosis. Today, the business has approximately 1,300 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts. www.emdserono.com

About Nebula Genomics

Nebula Genomics seeks to usher in the era of personal genomics by building a distributed platform that will accelerate genomic data generation, facilitate data access and streamline data analysis. The Nebula platform uses blockchain and privacy-preserving technologies to enable individuals to maintain control of their personal genomic data, share it securely and get compensated equitably. By incentivizing personal genome sequencing and genomic data sharing, Nebula Genomics will make large genomic datasets available to researchers which will help advance understanding of human genetics, accelerate drug discovery and streamline clinical trials. The company was founded by Harvard genomics pioneer George Church, along with Harvard researchers Dennis Grishin and Kamal Obbad. Founded in 2017, Nebula Genomics has offices in San Francisco, CA and Boston, MA and is backed by investors including Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, GreatPoint Ventures, Hemi Ventures and Mirae Asset. For more information, follow @NebulaGenomics on Twitter and Facebook or visit nebula.org.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190611005091/en/

CONTACT: Dennis Grishin, CSO, Nebula Genomics

dennis@nebula.org

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL

SOURCE: Nebula Genomics

Copyright Business Wire 2019.

PUB: 06/11/2019 09:00 AM/DISC: 06/11/2019 09:01 AM

http://www.businesswire.com/news/home/20190611005091/en

© 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Clear
80°
Humidity: 59%
Winds: E at 13mph
Feels Like: 82°

Your Extended Forecast

Tomorrow

weather
High 94°/Low 67°
Mostly clear. Lows overnight in the upper 60s.

monday

weather
High 92°/Low 70°
Times of sun and clouds. Highs in the low 90s and lows in the low 70s.

tuesday

weather
High 98°/Low 72°
More sun than clouds. Highs in the upper 90s and lows in the low 70s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7670 to sign up today.